Naga Koteswari Sucharita Cheedella, MD
Hematology & Oncology · San Antonio, TXNPI 1639588916
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,680 of the $3,642 with a category attached, or 73.6%. AstraZeneca accounts for 75.7% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $2,718, more than ten times the $49 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 40 payments — averaging $91.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Myriad Genetic Laboratories, Inc.$138
- Astellas Pharma US Inc$83
- Bayer$45
- EMD Serono, Inc.$44
- Pharmaessentia USA Corporation$35
- plus $539 from 26 others
Across 1 payment — averaging $18.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$19
What the payments were for
- Consulting fees$2,68074%
- Food & beverage$96226%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $2,757 |
| Myriad Genetic Laboratories, Inc. | 2 | $138 |
| Astellas Pharma US Inc | 4 | $83 |
| Bayer | 2 | $45 |
| EMD Serono, Inc. | 2 | $44 |
| Pharmaessentia USA Corporation | 1 | $35 |
| Tempus AI, Inc | 1 | $31 |
| Boehringer Ingelheim | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Genentech, Inc. | 1 | $24 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Octapharma USA, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Sanofi | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Novartis | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PreciseTumor$122
How this compares
$3,642 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $315 |
| Doxycycline Hyclate | 13 | $311 |
| Prochlorperazine Maleate | 12 | $75 |
| Potassium Chloride | 13 | $29 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.